ZYNERBA PHARMACEUTICALS INC CO Barclays PLC holding in Form 13-F
Barclays PLC reported holding of ZYNE
This chart displays the historical ownership data of ZYNE by Barclays PLC. At the end of Q2 2016 the holding was valued at $3,000.
| Date | Holding Value |
|---|---|
| 3000 | |
| 0 | |
| 209000 | |
| 10000 | |
| 4000 | |
| 49000 | |
| 10000 | |
| 119000 | |
| 0 | |
| 143000 | |
| 4000 | |
| 150000 | |
| 0 | |
| 136000 | |
| 2000 | |
| 96000 | |
| 6000 | |
| 5000 | |
| 31000 | |
| 29000 | |
| 0 | |
| 870000 | |
| 5000 | |
| 131000 | |
| 1000 | |
| 140000 | |
| 0 | |
| 46000 | |
| 37000 | |
| 15000 | |
| 0 | |
| 3000 | |
| 49000 | |
| 31000 | |
| 0 |
About ZYNERBA PHARMACEUTICALS INC CO
Zynerba Pharmaceuticals focuses on developing pharmaceutically-produced transdermal cannabinoid therapies, specifically targeting rare neuropsychiatric disorders such as Fragile X syndrome (FXS) and chromosome 22q11.2 deletion syndrome (22q). Their primary product candidate, Zygel (ZYN002), is a cannabidiol gel designed for transdermal delivery to treat behavioral symptoms associated with these conditions. Zygel is formulated to enhance the bioavailability of cannabidiol by bypassing the gastrointestinal tract and liver metabolism.
Zynerba operates within the pharmaceutical industry, concentrating on orphan neuropsychiatric disorders. The company generates revenue primarily through research grants and payments for research services, as it has not yet achieved commercial product revenue. Its main client base includes patients with high unmet medical needs for whom Zygel is being developed. The company's operational structure includes partnerships with contract manufacturers across the U.S., Canada, the U.K., and Australia for producing active pharmaceutical ingredients and drug products.
Key factors impacting Zynerba's business performance include the successful development and regulatory approval of Zygel, competition from other pharmaceutical firms, and the ability to secure favorable reimbursement from third-party payers. The company's financial health is also affected by its significant research and development expenses, as well as its accumulated operating losses.
Disclaimer
FilingExplorer.com is not affiliated with, endorsed by, or in any way officially connected with any of the securities, funds, or companies mentioned on this site. The information provided is sourced from publicly available datasets and is presented for informational purposes only. While we strive for accuracy, we do not guarantee the completeness, timeliness, or accuracy of any information on this site. Users should not rely solely on this information for making investment decisions and should always conduct their own research or consult with a qualified financial advisor. Security and company summaries are based on public data available in recent SEC filings, and may not be entirely accurate. The mention of any security does not constitute a recommendation to buy, sell, or hold that or any other security. FilingExplorer.com is not responsible for any investment decisions made based on the information provided on this site.
See our Terms of Service
Barclays PLC reported holdings of ZYNE from Q2 2016 to Q4 2021
| Reporting period | Holding Type | Market Value | % of portfolio | Shares | Change in shares | % Change in shares | Qtr end price |
|---|---|---|---|---|---|---|---|
| Q2 2016 | Stock | $3,000 | < 0.01% | 371 | 371 | 0 | $8.09 |
| Q3 2016 | Stock | $0 | 0 | 0 | -371 | -100.0% | - |
| Q1 2017 | Stock | $209,000 | < 0.01% | 10,400 | 10,400 | 0 | $20.10 |
| Q2 2017 | Stock | $10,000 | < 0.01% | 626 | -9,774 | -93.98% | $15.97 |
| Q3 2017 | Put | $4,000 | < 0.01% | 500 | 500 | 0 | $8.00 |
| Q3 2017 | Stock | $49,000 | < 0.01% | 5,827 | 5,201 | 830.83% | $8.41 |
| Q4 2017 | Call | $10,000 | < 0.01% | 800 | 800 | 0 | $12.50 |
| Q4 2017 | Stock | $119,000 | < 0.01% | 9,550 | 3,723 | 63.89% | $12.46 |
| Q4 2017 | Put | $0 | 0 | 0 | -500 | -100.0% | - |
| Q1 2018 | Stock | $143,000 | < 0.01% | 16,494 | 6,944 | 72.71% | $8.67 |
| Q1 2018 | Call | $4,000 | < 0.01% | 500 | -300 | -37.5% | $8.00 |
| Q2 2018 | Stock | $150,000 | < 0.01% | 15,400 | -1,094 | -6.63% | $9.74 |
| Q2 2018 | Call | $0 | 0 | 0 | -500 | -100.0% | - |
| Q3 2018 | Stock | $136,000 | < 0.01% | 16,672 | 1,272 | 8.26% | $8.16 |
| Q3 2018 | Call | $2,000 | < 0.01% | 200 | 200 | 0 | $10.00 |
| Q4 2018 | Stock | $96,000 | < 0.01% | 32,430 | 15,758 | 94.52% | $2.96 |
| Q4 2018 | Call | $6,000 | < 0.01% | 2,000 | 1,800 | 900.0% | $3.00 |
| Q1 2019 | Put | $5,000 | < 0.01% | 1,000 | 1,000 | 0 | $5.00 |
| Q1 2019 | Stock | $31,000 | < 0.01% | 5,698 | -26,732 | -82.43% | $5.44 |
| Q1 2019 | Call | $29,000 | < 0.01% | 5,400 | 3,400 | 170.0% | $5.37 |
| Q2 2019 | Put | $0 | 0 | 0 | -1,000 | -100.0% | - |
| Q2 2019 | Stock | $870,000 | < 0.01% | 64,200 | 58,502 | 1026.71% | $13.55 |
| Q2 2019 | Call | $5,000 | < 0.01% | 400 | -5,000 | -92.59% | $12.50 |
| Q3 2019 | Stock | $131,000 | < 0.01% | 17,546 | -46,654 | -72.67% | $7.47 |
| Q3 2019 | Call | $1,000 | < 0.01% | 100 | -300 | -75.0% | $10.00 |
| Q4 2019 | Stock | $140,000 | < 0.01% | 23,231 | 5,685 | 32.4% | $6.03 |
| Q4 2019 | Call | $0 | 0 | 0 | -100 | -100.0% | - |
| Q1 2020 | Stock | $46,000 | < 0.01% | 12,243 | -10,988 | -47.3% | $3.76 |
| Q2 2020 | Stock | $37,000 | < 0.01% | 11,057 | -1,186 | -9.69% | $3.35 |
| Q3 2020 | Stock | $15,000 | < 0.01% | 4,505 | -6,552 | -59.26% | $3.33 |
| Q4 2020 | Stock | $0 | 0 | 5 | -4,500 | -99.89% | - |
| Q1 2021 | Stock | $3,000 | < 0.01% | 739 | 734 | 14680.0% | $4.06 |
| Q2 2021 | Stock | $49,000 | < 0.01% | 9,211 | 8,472 | 1146.41% | $5.32 |
| Q3 2021 | Stock | $31,000 | < 0.01% | 7,268 | -1,943 | -21.09% | $4.27 |
| Q4 2021 | Stock | $0 | 0 | 0 | -7,268 | -100.0% | - |